FDA grants Breakthrough Therapy Designation to lung cancer therapy

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an investigational drug developed by SystImmune and Bristol Myers Squibb, for certain patients with advanced non-small cell lung cancer (NSCLC). The designation applies to patients whose tumours have specific epidermal growth factor receptor (EGFR) gene mutations, and whose […]